Davis Recognized as a Leader in Effort to Preserve Healthcare Assistance Program
The American Autoimmune Related Diseases Association recognized Davis and others for their leadership and continued advocacy in support of a critical healthcare assistance program
U.S. Representative Rodney Davis (R-Ill.) has been recognized by the American Autoimmune Related Diseases Association (AARDA) as a 2020 Outstanding Autoimmune Advocate for his leadership and continued advocacy in support of a critical healthcare assistance program. AARDA also recognized Representatives Don McEachin (D-VA-4), Bonnie Watson Coleman (D-NJ-12), and John Joyce (R-PA-13).
“Promoting the health and well-being of people with autoimmune diseases is a bipartisan policy goal that I’ve worked on with colleagues on both sides of the aisle,” said Rep. Davis. “Most recently, I teamed up with Congressman McEachin of Virginia and Congresswoman Watson Coleman of New Jersey, both of whom are Democrats, on legislation to prevent increased out-of-pocket costs for prescription drugs. Especially during this pandemic, we should be lowering financial barriers for individuals to get the prescriptions they need to stay healthy, particularly those with underlying medical conditions who are vulnerable to COVID-19. That’s why I’m proud to be recognized by the American Autoimmune Related Diseases Association. I look forward to continuing to work with the Association on policies and legislation that promote public health.”
"On behalf of AARDA, we sincerely thank Reps. McEachin, Davis, Watson Coleman, and Joyce for their tenacious efforts in opposition of this harmful, unnecessary change and urging for the revision, withdrawal, and delay of the rule that, if fully implemented, will undermine the ability of patients to access, afford, and adhere to prescribed medicines that assure their health and wellness,” said Randall Rutta, AARDA President and CEO. “We are deeply appreciative of their significant commitment to the health, well-being, and success of people with autoimmune diseases to help alleviate the suffering and the negative socioeconomic impact of autoimmunity,” said Rutta.
Recently, Rep. Davis worked with Democratic and Republican colleagues in introducing H.R. 7647, the bipartisan Preserving Patient Savings on Drug Costs Act, which stops insurers from instituting costly copay accumulator programs by delaying the Department of Health and Human Services’ (HHS) 2021 Notice of Benefit and Payment Parameter (NBPP) rule from going into effect until a year after the COVID-19 public health emergency has lifted. You can find out more about that legislation here.
The copay coupon assistance program is essential to patients in helping them better afford their medicines and stay healthy. In January, the Centers for Medicaid and Medicare Services (CMS) issued a NBPP that would allow insurance plans and others to no longer count the value of copay coupon assistance offered by manufacturers of prescription drugs against annual cost-sharing limitations. AARDA and 42 organizations expressed opposition to the rule, and AARDA conducted its Patients Deserve Better national campaign.
This harmful policy shift puts at risk the life-line to drug affordability that patients need, especially those suffering from serious illness, chronic conditions, and disabilities, including the estimated 50 million Americans with an autoimmune disease. This comes at a time when COVID-19 is eroding jobs, personal finances, and overall health for millions of families.
Representatives McEachin, Davis, Watson Coleman, and Joyce continue to oppose the harmful rule and remain consistent, strategic leaders in Congress and with other policymakers and regulators against changes to the copay coupon assistance program.
The American Autoimmune Related Diseases Association (AARDA) is dedicated to the eradication of autoimmune diseases and the alleviation of suffering and the negative socioeconomic effects of autoimmunity. Established in 1991, AARDA is the only national nonprofit organization committed to bringing a national focus to autoimmune diseases, which are a major cause of serious and chronic health conditions for an estimated 50 million Americans. AARDA actively supports people living with autoimmune diseases and their families through public awareness, patient education, research facilitation, advocacy, public policy reform, and stakeholder engagement. Learn more at www.aarda.org.